Exploring The Use of Enfortumab Vedotin in Rare Genitourinary Cancers

Commentary
Video
Conference|ASCO Annual Meeting: Genitourinary

Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.

Marijo Bilusic, MD, PhD spoke with CancerNetwork® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting about the planned investigation of enfortumab vedotin-ejfv (Padcev) with or without pembrolizumab (Keytruda) in less common genitourinary (GU) malignancies as part of the phase 2 E-VIRTUE trial (NCT06041503).1

Bilusic, a professor of Clinical Medicine and the Genitourinary Site Disease Group Leader at Sylvester Comprehensive Cancer Center of the University of Miami Health System, highlighted how this trial in progress aims to evaluate enfortumab vedotin-based treatment in patients who have no other standard therapy options available. If investigators observe a signal among this pretreated study population, Bilusic suggested that future work may involve incorporating the agent into earlier lines of treatment.

Based on prior reports, common toxicities associated with enfortumab vedotin may include rash, neuropathy, and blood glucose increases. According to Bilusic, becoming more comfortable with mitigating these adverse effects in this population is a matter of acquiring more experience with using the drug. Additionally, attending educational sessions may help clinicians understand the agent’s safety profile.

In the multi-center E-VIRTUE trial, investigators will evaluate treatment among patients 18 years and older with histologically confirmed advanced or metastatic pure adenocarcinoma of the urinary tract, pure squamous cell carcinoma of the urinary tract, or treatment-refractory testicular germ cell tumors.2

Transcript:

We are now targeting patients who have run out of standard options. The goal is to eventually move [enfortumab vedotin] earlier in the disease course so people [may receive it as] frontline therapy. If there’s a signal we see in the patients who are heavily pretreated, hopefully, we can move it earlier [and use it as] frontline therapy for those patients.

Based on the current information we have from the package insert [for enfortumab vedotin], we know there is some neuropathy. One of the main [adverse] effects was rash plus elevated blood glucose. Getting familiar with the package insert, managing drugs, and attending educational sessions can help us better manage these patients. It’s [about getting] experienced as we go. The same thing [happened] with immune checkpoint inhibitors. Ten years ago, [clinicians] didn’t have much experience. As we start using the drug more and more, reading about it, and attending educational sessions, I think we became more comfortable managing those [adverse] effects.

References

  1. Chandran E, Simon NI, da Motta Girardi D, et al. A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE). J Clin Oncol. 2024;42(suppl 16):TPS4628. doi:10.1200/JCO.2024.42.16_suppl.TPS4628
  2. Enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE). ClinicalTrials.gov. Accessed May 31, 2024. https://tinyurl.com/5cdjyb5a
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content
Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
August 2nd 2025
Article

Leading experts gathered in Orlando, Florida, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 1st 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Belzutifan Shows Superior Quality-Adjusted Survival in Advanced RCC

Ariana Pelosci
July 30th 2025
Article

Data from the LITESPARK-005 Q-TWiST analysis show belzutifan’s improved quality-adjusted survival time and favorable toxicity profile vs everolimus in RCC.